These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 29577969)

  • 41. Impact of benznidazole on infection course in mice experimentally infected with Trypanosoma cruzi I, II, and IV.
    Gruendling AP; Massago M; Teston AP; Monteiro WM; Kaneshima EN; Araújo SM; Gomes ML; Barbosa Md; Toledo MJ
    Am J Trop Med Hyg; 2015 Jun; 92(6):1178-89. PubMed ID: 25940197
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Chemotherapy with benznidazole and itraconazole for mice infected with different Trypanosoma cruzi clonal genotypes.
    Toledo MJ; Bahia MT; Carneiro CM; Martins-Filho OA; Tibayrenc M; Barnabé C; Tafuri WL; de Lana M
    Antimicrob Agents Chemother; 2003 Jan; 47(1):223-30. PubMed ID: 12499195
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Efficacy of novel benznidazole solutions during the experimental infection with Trypanosoma cruzi.
    Manarin R; Lamas MC; Bottasso E; Serra E; Revelli S; Salomón CJ
    Parasitol Int; 2013 Feb; 62(1):79-81. PubMed ID: 22975280
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Using Human Induced Pluripotent Stem Cell-Derived Cardiomyocytes as a Model to Study Trypanosoma cruzi Infection.
    Bozzi A; Sayed N; Matsa E; Sass G; Neofytou E; Clemons KV; Correa-Oliveira R; Stevens DA; Wu JC
    Stem Cell Reports; 2019 Jun; 12(6):1232-1241. PubMed ID: 31105048
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Technological innovation strategies for the specific treatment of Chagas disease based on Benznidazole.
    Ferraz LRM; Alves AÉG; Nascimento DDSDS; Amariz IAE; Ferreira AS; Costa SPM; Rolim LA; Lima ÁAN; Rolim Neto PJ
    Acta Trop; 2018 Sep; 185():127-132. PubMed ID: 29452113
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Impact of dual infections on chemotherapeutic efficacy in BALB/c mice infected with major genotypes of Trypanosoma cruzi.
    Martins HR; Silva RM; Valadares HM; Toledo MJ; Veloso VM; Vitelli-Avelar DM; Carneiro CM; Machado-Coelho GL; Bahia MT; Martins-Filho OA; Macedo AM; Lana M
    Antimicrob Agents Chemother; 2007 Sep; 51(9):3282-9. PubMed ID: 17638698
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Unveiling benznidazole's mechanism of action through overexpression of DNA repair proteins in Trypanosoma cruzi.
    Rajão MA; Furtado C; Alves CL; Passos-Silva DG; de Moura MB; Schamber-Reis BL; Kunrath-Lima M; Zuma AA; Vieira-da-Rocha JP; Garcia JB; Mendes IC; Pena SD; Macedo AM; Franco GR; de Souza-Pinto NC; de Medeiros MH; Cruz AK; Motta MC; Teixeira SM; Machado CR
    Environ Mol Mutagen; 2014 May; 55(4):309-21. PubMed ID: 24347026
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Limited Ability of Posaconazole To Cure both Acute and Chronic Trypanosoma cruzi Infections Revealed by Highly Sensitive In Vivo Imaging.
    Francisco AF; Lewis MD; Jayawardhana S; Taylor MC; Chatelain E; Kelly JM
    Antimicrob Agents Chemother; 2015 Aug; 59(8):4653-61. PubMed ID: 26014936
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Experimental benznidazole treatment of Trypanosoma cruzi II strains isolated from children of the Jequitinhonha Valley, Minas Gerais, Brazil, with Chagas disease.
    Oliveira-Silva JC; Machado-de-Assis GF; Oliveira MT; Paiva NC; Araújo MS; Carneiro CM; Martins-Filho OA; Martins HR; Lana Md
    Mem Inst Oswaldo Cruz; 2015 Feb; 110(1):86-94. PubMed ID: 25742267
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Comparative efficacies of TAK-187, a long-lasting ergosterol biosynthesis inhibitor, and benznidazole in preventing cardiac damage in a murine model of Chagas' disease.
    Corrales M; Cardozo R; Segura MA; Urbina JA; Basombrío MA
    Antimicrob Agents Chemother; 2005 Apr; 49(4):1556-60. PubMed ID: 15793138
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Pentamidine antagonizes the benznidazole's effect in vitro, and lacks of synergy in vivo: Implications about the polyamine transport as an anti-Trypanosoma cruzi target.
    Seguel V; Castro L; Reigada C; Cortes L; Díaz MV; Miranda MR; Pereira CA; Lapier M; Campos-Estrada C; Morello A; Kemmerling U; Maya JD; López-Muñoz R
    Exp Parasitol; 2016 Dec; 171():23-32. PubMed ID: 27729250
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Myocardial scars correlate with eletrocardiographic changes in chronic Trypanosoma cruzi infection for dogs treated with Benznidazole.
    Caldas IS; da Matta Guedes PM; dos Santos FM; de Figueiredo Diniz L; Martins TA; da Silva do Nascimento AF; Azevedo MA; de Lima WG; Neto RM; Torres RM; Talvani A; Bahia MT
    Trop Med Int Health; 2013 Jan; 18(1):75-84. PubMed ID: 23107306
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Development of In Vitro Drug-Induced Cardiotoxicity Assay by Using Three-Dimensional Cardiac Tissues Derived from Human Induced Pluripotent Stem Cells.
    Takeda M; Miyagawa S; Fukushima S; Saito A; Ito E; Harada A; Matsuura R; Iseoka H; Sougawa N; Mochizuki-Oda N; Matsusaki M; Akashi M; Sawa Y
    Tissue Eng Part C Methods; 2018 Jan; 24(1):56-67. PubMed ID: 28967302
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Nanomedicines against Chagas disease: an update on therapeutics, prophylaxis and diagnosis.
    Morilla MJ; Romero EL
    Nanomedicine (Lond); 2015 Feb; 10(3):465-81. PubMed ID: 25707979
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Looking for combination of benznidazole and Trypanosoma cruzi-triosephosphate isomerase inhibitors for Chagas disease treatment.
    Aguilera E; Varela J; Serna E; Torres S; Yaluff G; Bilbao NV; Cerecetto H; Alvarez G; González M
    Mem Inst Oswaldo Cruz; 2018 Mar; 113(3):153-160. PubMed ID: 29412353
    [TBL] [Abstract][Full Text] [Related]  

  • 56. A Novel High-Content Screening-Based Method for Anti-
    Portella DCN; Rossi EA; Paredes BD; Bastos TM; Meira CS; Nonaka CVK; Silva DN; Improta-Caria A; Moreira DRM; Leite ACL; de Oliveira Filho GB; Filho JMB; Dos Santos RR; Soares MBP; Souza BSF
    Stem Cells Int; 2021; 2021():2642807. PubMed ID: 34434238
    [TBL] [Abstract][Full Text] [Related]  

  • 57. An in vitro iron superoxide dismutase inhibitor decreases the parasitemia levels of Trypanosoma cruzi in BALB/c mouse model during acute phase.
    Olmo F; Urbanová K; Rosales MJ; Martín-Escolano R; Sánchez-Moreno M; Marín C
    Int J Parasitol Drugs Drug Resist; 2015 Dec; 5(3):110-6. PubMed ID: 26236582
    [TBL] [Abstract][Full Text] [Related]  

  • 58. A comparative study of posaconazole and benznidazole in the prevention of heart damage and promotion of trypanocidal immune response in a murine model of Chagas disease.
    Olivieri BP; Molina JT; de Castro SL; Pereira MC; Calvet CM; Urbina JA; Araújo-Jorge TC
    Int J Antimicrob Agents; 2010 Jul; 36(1):79-83. PubMed ID: 20452188
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Canova medication modifies parasitological parameters in mice infected with Trypanosoma cruzi.
    Pupulin AR; Marques-Araujo S; Toledo MJ; Gomes ML; Takejima E; Cuman RK; Bersani-Amado CA
    Exp Parasitol; 2010 Dec; 126(4):435-40. PubMed ID: 20433834
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Recent clinical trials for the etiological treatment of chronic chagas disease: advances, challenges and perspectives.
    Urbina JA
    J Eukaryot Microbiol; 2015; 62(1):149-56. PubMed ID: 25284065
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.